SHARE

NanoTech Entertainment, Inc. (OTCMKTS:NTEK), a market leader in bringing 4K content to users, is pleased to announce that its 4K Ultra HD Network UltraFlix has added 50 Bollywood movies to its platform.

As per the reports, the network has launched new Bollywood 4K Ultra HD Channel for Bollywood lovers across the country. It has added 50 movies as of now, but the number is likely to go up as the time passes and demand increases.

Insights On The Matter:

The company has signed a licensing agreement with a major Indian movie distributor named Film Karavan to make things fall in line. This licensing agreement facilitates the UltraFlix with access to Film Karavan’s movie library consisting full-length Indian movies. The network will also get the access to new releases from Film Karavan’s film partners from all over the world.

Some of the leading Bollywood movies that have got featured on UltraFlix are-

  • Drama: ISHAQZAADE, Mohabbatein, Kabhi Khushi Kabhie Gham
  • Romance: Jab Tak Hai Jaan, Fanaa, One By Two
  • Action Thriller: EK Tha Tiger, Gunday, Agneepath
  • Comedy: OMG Oh My God, Andaz Apna Apna, Hum Tum
  • Horror: DARR @ The Mall, Kahaani, Dhoom:3.

Film Karavan has been distributing top-notch Indian movies across the globe for years. After the association of Film Karavan with UltraFlix, the demand for Indian movies is likely to go up in the international market. The senior management of NanoTech is delighted to execute this agreement. According to Aaron Taylor, VP- Sales & Marketing, NanoTech, the primary focus of the company is to add a host of high definition movies to UltraFlix. The license agreement with Film Karavan will help the company in doing so without any hassle.

The demand of Indian movies has been increasing at international level; hence, this agreement with Film Karavan will not only help the company get new customers, but also enhance the overall value of the 4K platform.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

https://www.journaltranscript.com/disclaimer

LEAVE A REPLY